The frequency of IDH1 and IDH2 mutations are different in various tumor types: Thus, IDH1 and IDH2 are almost equally frequent in AML, while IDH1 mutations are predominant in gliomas, chondrosarcomas, and cholangiocarcinomas [8,9]. This evidence concerns the gene IDH1 and central nervous system cancer.